Artiva Biotherapeutics, Inc.
Datakwaliteit: 100%
ARTV
Nasdaq
Manufacturing
Chemicals
€ 6,68
▲
€ 0,49
(7,92%)
Marktkapitalisatie: 165,11 M
Prijs
€ 6,68
Marktkapitalisatie
165,11 M
Dagbereik
€ 6,13 — € 7,15
52-Weeksbereik
€ 1,47 — € 7,75
Volume
177.001
Openen € 6,13
50D / 200D Gem.
€ 5,16
29,36% above
50D / 200D Gem.
€ 3,74
78,59% above
Quick Summary
Belangrijkste Punten
Negative free cash flow of -79,34 M
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)-100,00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-60,28%
Onder sectorgemiddelde (-53,47%)
ROIC-47,88%
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current Ratio11,65
Interest CoverageN/A
Waardering
PE (TTM)
-1,97
Onder sectorgemiddelde (-1,47)
P/B Ratio1,28
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -2,0 | -1,5 |
| P/B | 1,3 | 1,6 |
| ROE % | -60,3 | -53,5 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -100,00% | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 0,0 | Net Income (TTM) | -83,87 M |
| ROE | -60,28% | ROA | -52,70% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -79,34 M |
| ROIC | -47,88% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 11,65 |
| Interest Coverage | N/A | Asset Turnover | 0,00 |
| Working Capital | 118,41 M | Tangible Book Value | 129,22 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -1,97 | Forward P/E | N/A |
| P/B Ratio | 1,28 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -48,05% | ||
| Market Cap | 165,11 M | Enterprise Value | 139,60 M |
| Per Share | |||
| EPS (Diluted TTM) | -3,43 | Revenue / Share | 0,00 |
| FCF / Share | -3,21 | OCF / Share | -3,11 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 94,60% |
| SBC-Adj. FCF | -87,46 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenue | 0,0 | 251.000,0 |
| Net Income | -83,87 M | -65,37 M |
| EPS (Diluted) | -3,43 | -5,81 |
| Gross Profit | — | — |
| Operating Income | -89,81 M | -67,28 M |
| EBITDA | — | — |
| R&D Expenses | 69,54 M | 50,33 M |
| SG&A Expenses | — | — |
| D&A | 2,60 M | 2,43 M |
| Interest Expense | — | — |
| Income Tax | 0,0 | 0,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 |
|---|---|---|
| Total Assets | 130,94 M | 209,58 M |
| Total Liabilities | 20,97 M | 22,94 M |
| Shareholders' Equity | 109,97 M | 186,64 M |
| Total Debt | — | — |
| Cash & Equivalents | 26,70 M | 40,24 M |
| Current Assets | 112,67 M | 188,63 M |
| Current Liabilities | 13,09 M | 12,25 M |
{"event":"ticker_viewed","properties":{"ticker":"ARTV","listing_kind":"stock","pathname":"/stocks/artv","exchange":"Nasdaq","country":"US"}}